FamiCord is excited to announce a restart of cooperation with Klara Medical Center, which specializes in stem cell therapy in adult patients. This partnership aims to enhance treatment options for patients in need of regenerative medicine therapy.

FamiCord Group- more than stem cells bank

FamiCord is more than just a stem cell bank; also we provide ATMP products based on umbilical cord stem cells, thanks to our two experienced CDMO centers in Canthanhede, Portugal, and Warsaw, Poland. This unique capability allows us to offer innovative therapeutic solutions that go beyond traditional cord blood banking, ensuring access to cutting-edge treatments for patients in need. As Dr. Tomasz Ołdak, Chief Technology Officer of PBKM, states, “This is made possible by FamiCord Group undergoing rigorous quality controls of our pharmaceutical manufacturing facilities.” ATMP stands for Advanced Therapy Medicinal Products, an umbrella term for innovative treatments including gene therapies, somatic cell therapies, and tissue-engineered products. These products are designed to address serious medical conditions by repairing, regenerating, or replacing damaged cells and tissues. ATMPs represent a new frontier in medicine, offering the potential for personalized and targeted therapies that can significantly improve patient outcomes. ATMPs can be used as registered products by the European Medicines Agency, as well as in special situations called hospital exemption (HE) which is a type of experimental application of ATMP in clinical situations where no other options exist. Our commitment to advancing regenerative medicine positions FamiCord as a leader in the field.

Klara Medical Center- new partner in hospital exemption therapy

Klara Medical Center is a private medical facility in Częstochowa, South-Western Poland. FamiCord Group has been working with Klara Medical Center for several years, and now, with the new project focused on the use of mesenchymal cells in experimental therapy for neurological diseases, we have once again confirmed our readiness to cooperate as a supplier of ATMP-HE products. "We are very pleased to continue this collaboration," said Tomasz Baran, VP of FamiCord Group. "This partnership allows us to advance innovative treatments and make a meaningful impact in the field of regenerative medicine." The project at Klara Medical Center is coordinated by Dr. Beata Świątkowska-Flis, a neurologist with extensive experience in the application of stem cells in neurology. The project focuses on neurological and ophthalmological diseases, and the biological material used for ATMP production comes from unrelated donors. A physician must enroll patients to participate in the therapy under this project. MORE ABOUT THE PROJECT AND QUALIFICATION CRITERIA HERE

Organizational Aspects of Stem Cell Therapy: Key Insights and Guidelines

Stem cell therapies performed at Klara Medical Center are experimental procedures. We cannot guarantee specific treatment outcomes or a cure for their condition. Given that stem cell therapy is experimental, patients participating in the project must be under the care of an association or medical agency that will cover the costs of the therapy on their behalf.

We chose ReproAdvice MedComms&Consulting led by Karina M. Sasin, M.D. PhD to support our international patients.  Karina has been coordinating international patient flow in various projects for several years and has extensive research experience in rare diseases, epidemiology, and reproductive health. As the single point of contact for patients and referring physicians, she will take comprehensive care of and accompany them all along the way from initial screening, through enrollment, treatment, and follow-up. The agency will provide all the necessary financial arrangements, translations, and travel arrangements if requested.